Company intelligence / Profile preview

Neuromed Vet

Milan, Italy

Ownership: Private
Development stage: Other

Overview

Neuromed Vet is an Italian biotechnology company specializing in the development of innovative pharmacological and nutraceutical solutions for neurological disorders in companion animals. The company focuses on modulating neuroinflammation and the endocannabinoid system, particularly through the use of ultra-micronized palmitoylethanolamide (PEA-um). Their product portfolio targets chronic conditions such as canine and feline epilepsy, neuropathic pain, and cognitive decline in aging pets. Neuromed Vet bridges the gap between human neuropharmacology and veterinary medicine to improve the quality of life for pets with complex neurological needs.

Therapeutic areas: Neurology
Modalities: Small moleculeNutraceutical
Industry: Veterinary

Beyond the preview

Go deeper on Neuromed Vet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuromed Vet.

Explore the full profile